These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35867411)

  • 1. Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant.
    Dimeglio C; Herin F; Da-Silva I; Gernigon C; Porcheron M; Chapuy-Regaud S; Izopet J
    Microbiol Spectr; 2022 Aug; 10(4):e0270621. PubMed ID: 35867411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
    Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
    mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.
    Lin YJ; Evans DH; Robbins NF; Orjuela G; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2023 Aug; 11(4):e0525622. PubMed ID: 37289096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.
    Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
    Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
    Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers.
    Benning L; Morath C; Bartenschlager M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schaier M; Klein K; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
    Clin Microbiol Infect; 2022 Jul; 28(7):1024.e7-1024.e12. PubMed ID: 35124261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
    Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
    mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
    Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
    Front Immunol; 2022; 13():968105. PubMed ID: 36211416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
    Manali M; Bissett LA; Amat JAR; Logan N; Scott S; Hughes EC; Harvey WT; Orton R; Thomson EC; Gunson RN; Viana M; Willett B; Murcia PR
    J Infect Dis; 2022 Dec; 227(1):40-49. PubMed ID: 35920058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections.
    Zou J; Xie X; Liu M; Shi PY; Ren P
    mBio; 2022 Aug; 13(4):e0199622. PubMed ID: 35924850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.